Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
InVitae Corp is a diagnostics & research business based in the US. InVitae shares (NVTA) are listed on the NYSE and all prices are listed in US Dollars. InVitae employs 2,900 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $3.07 |
|---|---|
| 52-week range | $2.08 - $35.51 |
| 50-day moving average | $4.12 |
| 200-day moving average | $13.93 |
| Wall St. target price | $13.59 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.06 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.07 from 2022-06-24
| 1 week (2022-06-17) | 37.67% |
|---|---|
| 1 month (2022-05-27) | -23.63% |
| 3 months (2022-03-23) | N/A |
| 6 months (2021-12-27) | -79.78% |
| 1 year (2021-06-25) | -91.09% |
|---|---|
| 2 years (2020-06-26) | -88.99% |
| 3 years (2019-06-27) | 21.55 |
| 5 years (2017-06-26) | 9.64 |
| Revenue TTM | $480.5 million |
|---|---|
| Gross profit TTM | $111.8 million |
| Return on assets TTM | -11.74% |
| Return on equity TTM | -17.29% |
| Profit margin | -93.93% |
| Book value | $12.43 |
| Market capitalisation | $644.3 million |
TTM: trailing 12 months
We're not expecting InVitae to pay a dividend over the next 12 months.
Over the last 12 months, InVitae's shares have ranged in value from as little as $2.08 up to $35.51. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while InVitae's is 1.9047. This would suggest that InVitae's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.